공시 • Nov 17
Endonovo Therapeutics, Inc. announced delayed 10-Q filing On 11/15/2023, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Oct 13
Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA Approval Endonovo Therapeutics, Inc. announced the full regulatory approval of its product, SofPulse® by the Taiwan Food and Drug Administration (TFDA), the regulatory division of the Ministry of Health and Welfare (MOHW). The approval is a significant accomplishment in introducing innovative Pulsed Electro Magnetic Field (PEMF) technology into the Taiwanese surgical market through Endonovo's valued distribution partner, EverMed Medical Enterprises Co. The SofPulse® TFDA approval marks the initial phase of Endonovo's expansion, through EverMed, into the largely untapped PEMF and surgical sectors in Taiwan. Initial sales efforts will focus on introducing SofPulse® into multiple Taiwanese hospital surgical markets. EverMed will target four surgical specialties -- including cardiovascular surgery, orthopedic surgery, spinal surgery and plastic surgery -- representing hundreds of thousands of surgical cases. SofPulse® Commercialization in Taiwan: EverMed and Endonovo’s commercialization of SofPulse® in Taiwan commences with product registration with the NHI. This will be followed by an extensive sales and marketing campaign to introduce surgeons and patients to the benefits of PEMF therapy. Sales and marketing strategies include leveraging existing connections with MD’s, surgeons, hospitals and medical facilities to promote the expansion of surgical applications across Taiwan's three regions. As healthcare professionals and patients experience the tangible benefits of PEMF technology in post-operative care, SofPulse® is poised for success and wide acceptance throughout the Taiwanese surgical market. Taiwan FDA Process and International Expansion: The TFDA is the regulatory arm of Taiwan’s MOHW and is considered the driving force behind healthcare improvement in Taiwan. MOHW's focus is on promoting the health and well-being of all citizens in Taiwan by improving healthcare quality, advancing technological development, ensuring quality, efficiency, resource allocation contributing to international affairs. SofPulse® TFDA approval helps to validate Endonovo’s innovative approach to pain relief and non-opioid alternatives that has garnered widespread attention in the ever-growing global medical markets. 공시 • Aug 17
Endonovo Therapeutics, Inc. announced delayed 10-Q filing On 08/15/2023, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • May 17
Endonovo Therapeutics, Inc. announced delayed 10-Q filing On 05/16/2023, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Dec 01
Endonovo Therapeutics, Inc. Appoints Ira Weisberg President to Guide Global Medical Expansion Endonovo Therapeutics, Inc. appointed Ira Weisberg as President and Chief Commercial Officer of its Medical Division. Weisberg has more than four decades of experience in healthcare and pharmaceutical management, business development, finance, sales and marketing. Weisberg’s past work experience includes positions as President and CEO of Amherst Pharmaceuticals, Senior VP and Corporate Development Officer at Neurotrope Bioscience. Other executive medical administrative experience include executive positions at ALPHAVAX, INC., LIFECYCLE PHARMA, CHUGAI PHARMA USA, HAEMACURE CORPORATION and AVENTIS BEHRING. 공시 • Nov 15
Endonovo Therapeutics, Inc. announced delayed 10-Q filing On 11/14/2022, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Sep 29
Endonovo Therapeutics, Inc. (OTCPK:ENDV) entered into an Asset Purchase Agreement to acquire Substantially all of the assets and assume certain liabilities of Western Star. Endonovo Therapeutics, Inc. (OTCPK:ENDV) entered into an Asset Purchase Agreement to acquire Substantially all of the assets and assume certain liabilities of Western Star Concrete, LLC from for $25.2 million on September 26, 2022. The deal is conditioned on Employment Agreements signed by Endonovo Therapeutics, The transaction is subject to Due diligence, and audit of Western Star’s financial statements for the years ended December 31, 2021 and December 31. The closing is anticipated to be held on or about December 15, 2022. Jack B. Eggleston of Eggleston King Davis, LLP acted as legal advisor to Endonovo Therapeutics. 공시 • Aug 16
Endonovo Therapeutics, Inc. announced delayed 10-Q filing On 08/15/2022, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Jul 29
Endonovo Therapeutics Releases Comparative Analysis Demonstrating Endonovo Therapeutics, Inc. released superior comparative results for its SofPulse® medical device for post-operative pain relief compared with Bioelectronics Corporation’s RecoveryRx®. The medical treatment comparisons were clinically evaluated based on three clinical trials for RecoveryRx® and five published studies for SofPulse®. Product and technical characteristics comparisons for both devices were included in FDA-clearance material for both company’s Pulsed Electric Magnetic Frequency (PEMF) products, which are designed to alleviate post-operative reduction of pain and edema (swelling). Comparison of SofPulse® to RecoveryRx® in technical characteristics demonstrated superiority of the design, efficacy and health benefits of the Endonovo SofPulse® medical device. 공시 • May 17
Endonovo Therapeutics, Inc. announced delayed 10-Q filing On 05/16/2022, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Apr 16
Endonovo Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt Endonovo Therapeutics, Inc. filed its 10-K on Apr 14, 2022 for the period ending Dec 31, 2021. In this report its auditor, Rose, Snyder & Jacobs, gave an unqualified opinion expressing doubt that the company can continue as a going concern. 공시 • Apr 01
Endonovo Therapeutics, Inc. announced delayed annual 10-K filing On 03/31/2022, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. 공시 • Mar 03
Endonovo Therapeutics Inc. Appoints Garry Michael Kann as Head of Corporate Development Endonovo Therapeutics Inc. announced that it has appointed Garry Michael Kann as Head of Corporate Development to design, lead and execute its new corporate “build up strategy” of identifying and acquiring complementary specialty service providers in the construction industry. Mr. Kann will be responsible for management and oversight of creation and ongoing operation of all corporate development activities including oversight of potential acquisitions (Targets) identification activities, discussions regarding structuring of Transactions for Endonovo and management and oversite of Endonovo Merger and Acquisition staff. By Endonovo, establishing a Mergers and Acquisition division run by Mr. Kann, Endonovo will become a diversified holding company. 공시 • Aug 17
Endonovo Therapeutics, Inc. announced delayed 10-Q filing On 08/16/2021, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • May 18
Endonovo Therapeutics, Inc. announced delayed 10-Q filing On 05/17/2021, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Apr 02
Endonovo Therapeutics, Inc. announced delayed annual 10-K filing On 03/31/2021, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. 공시 • Nov 18
Endonovo Therapeutics, Inc. announced delayed 10-Q filing On 11/16/2020, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Oct 10
Endonovo Therapeutics’ Offers FDA Cleared Solution to Opioid Epidemic Which Has Significantly Increased During the COVID Pandemic Endonovo Therapeutics, Inc. announced a new marketing and public awareness campaign around their FDA Cleared SofPulse® that has been proven to help the in the response to the opioid epidemic during the COVID pandemic. SofPulse® device is FDA Cleared for reduction of pain and edema post-operatively. It offers a non-opioid, non-invasive, non-pharmaceutical opioid mitigation treatment and it has no known side effects based upon over 20,000+ surgical uses since its introduction to post-surgical pain management. Management believes that SofPulse® is a viable solution to manage pain and edema for all in-patient hospital surgeries. However, the true value of adopting this preventative approach to the opioid epidemic is in the lives saved. 공시 • Aug 12
Endonovo Therapeutics, Inc. announced delayed 10-Q filing On 08/11/2020, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.